News
Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
According to the FDA, Comirnaty has the same formulation as the Pfizer COVID-19 vaccine that was previously authorized for emergency use (EUA) in the United States. It will continue to be ...
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback